ArticleFrontiers in behavioral neuroscience2025
Alteration of hippocampal parvalbumin interneurons underlies memory impairment in rat model of Parkinson's disease.
Article in Frontiers in behavioral neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive decline is a major non-motor symptom in patients with Parkinson's disease (PD) that can be present as early as the prodromal stage. As a multisystem neurodegenerative syndrome, PD is associated with disturbances in various neurotransmitters, including dopamine, acetylcholine, serotonin, noradrenaline, glutamate, and gamma-aminobutyric acid (GABA). While the roles of dopaminergic and cholinergic deficiencies in cognitive impairment in PD are well documented, the contribution of the GABAergic system is less clear. We investigated spatial and recognition memory, along with changes in hippocampal GABAergic parvalbumin-positive (PV+) neurons, in distinct rat models of PD neuropathology. PD cholinopathy was induced by bilateral pedunculopontine tegmental nucleus (PPT) lesion, hemiparkinsonism was induced by unilateral substantia nigra pars compacta (SNpc) lesion, and hemiparkinsonism with PD cholinopathy was induced by unilateral SNpc and bilateral PPT lesions. Behavioral tests were conducted 14 and 42 days after lesions and included assessments of spatial memory (spatial habituation test), recognition memory (novel object recognition test), and measurements of motor activity (open field test). Motor function was preserved in all PD models. We observed delayed impairments in spatial and recognition memory in PD cholinopathy, and persistent impairment in spatial memory in hemiparkinsonism, although hippocampal PV expression remained unchanged over time. In hemiparkinsonism with PD cholinopathy, persistent spatial memory impairment was followed by delayed recognition memory deficits, along with hippocampal PV suppression, which was functionally linked to recognition memory impairment. Our results show that different PD neuropathologies underlie different memory impairments in rats. While dopaminergic denervation plays an important role in impairing spatial memory from the prodromal stage of PD, cholinergic denervation impairs recognition memory in a delayed manner. However, only their synergistic dysfunction alters hippocampal GABAergic PV+ neuron-mediated inhibitory transmission during PD progression, which was correlated with memory impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.